MTOR and cancer: Although the performance of the tested mTOR inhibitors in cancer therapy was moderate, it is still believed that the full therapeutic potential of targeting mTOR has yet to be exploited [19,77], and NP-based medicines are thought to have the ability to overcome the problems presented by regular drugs in mTOR signaling modulation.